Meeting
2018 ASCO Annual Meeting
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement.
Authors
Elena Fountzilas
The University of Texas MD Anderson Cancer Center, Houston, TX
Elena Fountzilas , Elangovan Krishnan , Filip Janku , Siqing Fu , Daniel D. Karp , Aung Naing , Vivek Subbiah , David S. Hong , Sarina Anne Piha-Paul , David J Vining , Apostolia Maria Tsimberidou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Chemotherapy
Clinical Trial Registration Number
NCT01213238
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2527)
DOI
10.1200/JCO.2018.36.15_suppl.2527
Abstract #
2527
Poster Bd #
353
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu
Poster
2019 Gastrointestinal Cancers Symposium
CD276-positive circulating endothelial cells in advanced colorectal cancer.
First Author: Elske C. Gootjes
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
First Author: Fatima A. Rangwala
Poster
2011 ASCO Annual Meeting
A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer.
First Author: W. M. D. Tai